YMAB
Companies
NASDAQ
Y-mAbs Therapeutics Inc.
Health Care
$4.63
-$3.20 (-40.87%)
Price Chart
Overview
About YMAB
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
Market Cap
$525.7M
Volume
1.0M
Avg. Volume
1.0M
P/E Ratio
-7.2931037
Dividend Yield
0.00%
Employees
110.0
Company Information
Risk & Correlation Analysis
Market Correlation
1.48
High Correlation
Volatility
High (0.65)
Relative to market
Macro Factor Sensitivities
Interest Rates
Medium Sensitivity
Inflation
High Sensitivity
GDP Growth
High Sensitivity
Liquidity
High Sensitivity
Commodity Prices
High Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, YMAB shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$525.7M
Volume1.0M
P/E Ratio-7.29
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 13, 2025Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025